China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
Mon 11:27
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion Oct 19 (Reuters) - China's Hansoh Pharmaceutical 3692.HK said on Monday its units have entered into a collaboration and licensing deal with Roche ROPC.S potentially worth more than $15 billion, covering a portfolio of antibody-drug conjugate programs.
Under the deal, Hansoh will receive an upfront payment of $400 million, a first anniversary payment of $110 million, and further milestone payments.
(Reporting by Nichiket Sunil in Bengaluru; Editing by Leroy Leo)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey